All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
After removal of the precursor signal peptide, proinsulin is post-translationally cleaved into three peptides: the B chain and A chain peptides, which are covalently linked via two disulfide bonds to form insulin, and C-peptide. Binding of insulin to the insulin receptor (INSR) stimulates glucose uptake. A multitude of mutant alleles with phenotypic effects have been identified. There is a read-through gene, INS-IGF2, which overlaps with this gene at the 5' region and with the IGF2 gene at the 3' region. Alternative splicing results in multiple transcript variants.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-YC0174 | Anti-INS (E2E3) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Pig | E2E3 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC0175 | Anti-INS (IN-05) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Pig | IN-05 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC0262 | Anti-INS (D3E7) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Human | D3E7 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC0263 | Anti-INS (D6C4) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Human | D6C4 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC1074 | Anti-INS (E2E3) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Pig | E2E3 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC1075 | Anti-INS (IN-05) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Pig | IN-05 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC1162 | Anti-INS (D3E7) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Human | D3E7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC1163 | Anti-INS (D6C4) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Human | D6C4 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ1432 | Anti-INS (CBXC-2037) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2037 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ1433 | Anti-INS (CBXC-2256) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2256 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ1434 | Anti-INS (CBXC-1353) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-1353 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ1435 | Anti-INS (CBXC-2423) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2423 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ4856 | Anti-INS (CBXC-2037) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2037 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ4857 | Anti-INS (CBXC-2256) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2256 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ4858 | Anti-INS (CBXC-1353) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-1353 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ4859 | Anti-INS (CBXC-2423) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2423 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-WFY3087 | Anti-INS (CBFYC-2782) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-2782 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-WFY3088 | Anti-INS (CBFYC-2783) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-2783 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-WFY3089 | Anti-INS (CBFYC-2784) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-2784 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-WFY6340 | Anti-INS (CBFYC-2782) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-2782 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION